MORPHOSYS AG O.N. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 7.31
Dividend & YieldN/A€ (N/A)
Beta 0.52
Market capitalization 442.38M
Operating cash flow -417.2M
ESG Scores unknown

Company description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio3.91
Working Capital-0.61
Return On Equity-2.1
Debt To Equity1.15
Fixed Asset Ratio0.37
Fixed Interest Cover-3.87

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 4.28M 13.94M 78.44M -93.18M
Total Cashflows From Investing Activities -177.75M 79.48M -879.62M -831.01M
Net Borrowings 1.02M -2.35M 317.16M -3.13M
Total Cash From Financing Activities 179.46M 353.24k 907.19M 1.32B
Change To Operating Activities -2.72M 316.29k -8.49M
Issuance Of Stock 193.61M 3.71M 81.37M 84.97M
Net Income -56.17M -103.01M 97.89M -514.46M
Change In Cash -31.13M -1.15M 65.48M 13.45M
Effect Of Exchange Rate -59.46k 87.11k 3.4M 2.99M
Total Cash From Operating Activities -32.78M -81.07M 35.27M -481.45M
Depreciation 3.75M 6.25M 8.25M 10M
Change To Account Receivables -6.61M 2.67M -69.62M 10.53M
Other Cashflows From Financing Activities -15.17M -1.01M 508.66M 1.24B
Change To Netincome 24.15M 3.2M -71.28M 135.92M
Capital Expenditures -1.82M -3.1M -4.46M -3.81M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 87.21M 106.78M 125.32M 220.5M
Income Before Tax -60.48M -106.52M 22.49M -591.05M
Net Income -56.17M -103.01M 97.89M -514.46M
Selling General Administrative 28.31M 59.34M 159.23M 181.7M
Gross Profit 74.65M 59.67M 318.52M 147.42M
Ebit -40.87M -106.45M 33.98M -254.79M
Operating Income -40.87M -106.45M 33.98M -254.79M
Interest Expense -179k -1.02M -19.98M -65.82M
Income Tax Expense -4.3M -3.51M -75.4M -76.59M
Total Revenue 76.44M 71.76M 327.7M 179.61M
Cost Of Revenue 1.8M 12.09M 9.17M 32.19M
Total Other Income ExpenseNet -19.6M -71.83k -11.49M -336.26M
Net Income From Continuing Ops -56.17M -103.01M 97.89M -514.46M
Net Income Applicable To Common Shares -56.17M -103.01M 97.89M -514.46M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 50.39M 101.74M 1.04B 2.31B
Total Stockholder Equity 488.37M 394.7M 621.32M 244.88M
Other Current Liabilities 5.08M 9.08M 86.24M 109.53M
Total Assets 538.76M 496.44M 1.66B 2.56B
Common Stock 31.84M 31.96M 32.89M 34.23M
Other Current Assets 1.38M 4.79M 10M 15.95M
Retained Earnings -152.77M -255.78M -157.89M -672.35M
Treasury Stock -10.61M -9.65M -2.66M 49.67M
Cash 45.46M 44.31M 109.79M 123.25M
Total Current Liabilities 45.92M 61.56M 200.46M 284.54M
Other Stockholder Equity -210.89k -1.3M 2.21M 52.76M
Property, Plant, and Equipment 3.53M 47.81M 50.74M 49.59M
Total Current Assets 388.91M 303.69M 1.21B 1.13B
Net Tangible Assets 441.01M 349.9M 550.33M -929.02M
Net Receivables 20.74M 20.34M 89.84M 85.79M
Accounts Payable 7.21M 10.66M 47.82M 73.79M


Insider Transactions

Here are the insider transactions of stock shares related to MORPHOSYS AG O.N.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to MORPHOSYS AG O.N.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on MORPHOSYS AG O.N.

Here is the result of two systematic investment strategies applied to MORPHOSYS AG O.N.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on MORPHOSYS AG O.N.

The following chart shows the equity curve of the two systematic investment strategies applied to MORPHOSYS AG O.N.:

MORPHOSYS AG O.N. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -56.48% on the backtest period.

Performance at glance

Performance

-56.48 %

Latent gain

-883.84 €

Invested capital

1564.78 €

Annualized return

-13.71 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on MORPHOSYS AG O.N.

This is the result of two momentum investment strategies applied to MORPHOSYS AG O.N.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on MORPHOSYS AG O.N.

The following chart shows all the entries opened by the momentum investment system on MORPHOSYS AG O.N.:

MORPHOSYS AG O.N. momentum entries
  • The first momentum investment strategy would give -57.92% of return on MORPHOSYS AG O.N.. That represents -2030.93€ of latent gain with 3506.3€ of employed capital.
  • The second momentum investment strategy would give -59.82% of return on MORPHOSYS AG O.N.. That represents -2027.4€ of latent gain with 3389.28€ of employed capital.
Performance at glance (1Q Momentum)

Performance

-57.92 %

Latent gain

-2030.93 €

Invested capital

3506.3 €

Annualized return

-14.91 %
Performance at glance (2Q Momentum)

Performance

-59.82 %

Latent gain

-2027.4 €

Invested capital

3389.28 €

Annualized return

-16.43 %

Momentum equity curve on MORPHOSYS AG O.N.

The following chart shows the equity curve of the two momentum strategies applied to MORPHOSYS AG O.N.:

MORPHOSYS AG O.N. momentum equity

Note: the dividends potentially given by MORPHOSYS AG O.N. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MORPHOSYS AG O.N.

The following chart shows the employed capital evolution of the two momentum strategies on MORPHOSYS AG O.N. since the beginning:

MORPHOSYS AG O.N.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on MORPHOSYS AG O.N.

Buy the dip entry openings on MORPHOSYS AG O.N.

MORPHOSYS AG O.N.

The performance achieved by the robo-advisor on MORPHOSYS AG O.N. is -31.61%. That represents -542.02$ of latent gain with 1714.75€ of employed capital. The following chart shows MORPHOSYS AG O.N. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of MORPHOSYS AG O.N., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-31.61 %

Latent gain

-542.02 €

Invested capital

1714.75 €

Annualized return

-14.91 %

Equity curve of the strategy applied to MORPHOSYS AG O.N.

The following chart shows the result of the investment strategy applied to MORPHOSYS AG O.N.:

MORPHOSYS AG O.N.

Note: the dividends potentially given by MORPHOSYS AG O.N. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MORPHOSYS AG O.N.

The following chart shows the employed capital evolution since the beginning of the investment strategy on MORPHOSYS AG O.N.:

MORPHOSYS AG O.N.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on MORPHOSYS AG O.N.

In this section, I will compare the three previous investment strategies applied to MORPHOSYS AG O.N..

Equity curve comparison on MORPHOSYS AG O.N.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

MORPHOSYS AG O.N. investment strategy comparison

Employed capital comparison on MORPHOSYS AG O.N.

MORPHOSYS AG O.N. investment comparison

Performance comparison on MORPHOSYS AG O.N.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -56.48% -883.84€ 1564.78€ -13.71%
Momentum 1 quarter -57.92% -2030.93€ 3506.3€ -14.93%
Momentum 2 quarters -59.82% -2027.4€ 3389.28€ -16.43%
Non-directional -31.61% -542.02€ 1714.75€ -14.91%
Annualized return comparison

Automatic investment

-13.71 %

Momentum 1Q

-16.43 %

Momentum 2Q

-16.43 %

Non-directional

-14.91 %

Correlated stocks

Here are the most positively and negatively correlated stocks with MORPHOSYS AG O.N.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between MORPHOSYS AG O.N. and the other stocks. There may be false positives or some missing correlated stocks. If the price of MORPHOSYS AG O.N. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name MORPHOSYS AG O.N.
Country Germany
City Planegg
Address Semmelweisstrasse 7
Phone 49 89 89927 0
Website www.morphosys.com
FullTime employees 627
Industry Biotechnology
Sector Healthcare
Exchange XETRA
Ticker MOR.XETRA
Market www.xetra.com

MORPHOSYS AG O.N. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown